Every previous GLP-1 medication, including semaglutide and tirzepatide, shows weight loss plateaus by 60 to 72 weeks
2,48 Concern about the risk of pancreatitis increased after GLP-1 receptor agonist indications for use expanded to include cardiovascular and renal protection, obesity and metabolic dysfunctionassociated fatty liver disease (MAFLD
Some private clinics also prescribe it off-label for weight loss
In receptor pharmacology studies, Retatrutide demonstrates agonist activity at all three receptors, although experimental characterization suggests different relative potency across the receptor set
The titration schedule is a guideline, not a requirement
They can be injected under the skin of the upper arm, stomach or thigh